Investors
and Media
News Releases
-
Feb 12, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended...
-
Feb 3, 2020- Brings to Portola 20 Years of Clinical Development and Approval Experience -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Rajiv Patni, M.D., as executive vice president and chief medical officer, effective immediately. Dr. Patni brings...
-
Jan 9, 2020- Fourth Quarter Net Revenues of Andexxa Expected to be Approximately $28 Million Including $4 Million in Fourth Quarter Sales from Ondexxya in Europe -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the fourth quarter, the Company...
-
Dec 23, 2019
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020. The event is scheduled to take place on
-
Dec 17, 2019- American Heart Association Quality Improvement Project Promotes Patient Education and Physician Best Practices for Hemorrhagic Stroke -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative for enhanced awareness and...